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Abstract
Introduction: American tegumentary leishmaniasis (ATL) is a zoonotic disease caused by 
protozoan parasites of the genus Leishmania that affects the skin and mucous membrane. 
Currently, the available drugs for the treatment are injectable, with side effects, long-term 
treatment regimen and there is the possibility of drug resistance. Thus, alternative therapies have 
been tested, including photodynamic therapy (PDT). We evaluated the efficacy of PDT on its 
own and associated with the prescribed ATL treatment. 
Methods: BALB/c mice were infected with Leishmania (Leishmania) amazonensis and divided 
into 6 groups: Gluc+PDT, treated with Glucantime® and photodynamic therapy (PDT) with 
methylene blue (MB)/red LED (light-emitting diode); Gluc, treated with Glucantime®; PDT, 
treated with PDT with MB/red LED; Ampho+PDT, treated with amphotericin and PDT with 
MB/red LED; Ampho, treated with amphotericin; and control, which were infected but not 
treated. Two treatment cycles were performed. After 165 days of infection, the parasite load was 
determined. 
Results: Statistical differences were not found (P > 0.05) between measures of volume and 
thickness of the infected footpads in the treated groups when compared with the control group. 
However, there was a significant reduction (P < 0.05) in the parasitic load of the popliteal lymph 
nodes of the Gluc+PDT, Gluc, PDT and Ampho groups when compared to the control group. 
In the histological analysis of the infected footpads, the Gluc+PDT group presented a smaller 
amount of amastigote nests and lower intensity of the mononuclear infiltrate when compared to 
the Gluc and PDT groups. 
Conclusion: The results showed that although there is no significant difference in the evaluations 
of footpad size (thickness and volume), there is a downward measurement tendency in the 
Gluc+PDT group, as it can be observed by volume data and corroborated by parasite negative 
load.
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Introduction
 Leishmaniasis is an infectious parasitic disease considered 
by the World Health Organization (WHO) as one of the 
major world endemics due to its high detection coefficient 
and high capacity of producing deformities. It is estimated 
that 12 million people are infected in the whole world and 
350 million are at risk of becoming ill.1-3
In Brazil, American tegumentary leishmaniasis (ATL) is 
endemic and represents the second most spread tropical 
disease.4 ATL is an infectious and non-contagious 
disease, caused by several species of protozoa of the 
genus Leishmania which affects the skin and mucous 
membranes, and it clinically appears as cutaneous (CL), 
mucous cutaneous (MCL) and diffuse cutaneous (DCL). 
The CL form is the most common, being responsible for 
more than 90% cases in Brazil.3 It is estimated that 3% to 
5% of CL cases develop mucosal lesions.4
Nowadays, the medicines available in Brazil to treat 
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leishmaniasis are injectable, through intramuscular 
or intravenous administration. The drugs used are 
pentavalent antimonials (first choice), amphotericin B and 
pentamidine (second choice).5 However, these drugs cause 
severe side effects, such as cardiotoxicity, pancreatitis, 
leukopenia, thrombocytopenia, hepatotoxicity and 
nephrotoxicity, besides requiring prolonged time to 
eliminate the infection, which, in many cases, causes the 
abandonment of therapy.6-12 In addition to serious adverse 
effects, reports of the existence of primary and secondary 
resistance to antimonials may also contribute to the 
failure of treatment of ATL.13 
Considering the toxicity, injectable administration, cost 
and resistance to medicines, added over the long treatment 
time, alternative forms of therapy have been tested, among 
these, the photodynamic therapy (PDT).6,14-16
PDT is based on the application of a photosensitive 
substance on the target lesion, which, by receiving the 
adequate wavelength light, is activated and triggers a 
series of reactions in the presence of molecular oxygen, 
resulting in the production of reactive oxygen species, 
leading to cell death and destruction of diseased tissue.17 
The simultaneous presence of light, photosensitizing 
agent and oxygen is fundamental for PDT.17,18 Currently, 
PDT is used in medical areas mainly for the treatment of 
tumors and some benign dermatological diseases.19
Photosensitizers may be dyes, which are photosensitive 
substances, usually nontoxic for topical application, 
characterized by a high capacity to absorb visible 
light. Some of these compounds are capable of 
reacting photochemically, which turns them into 
therapeutic agents.18 One example is methylene blue 
(MB), used in medical practice for many years to treat 
methemoglobinemia, malaria and as urinary antiseptic in 
the absence of light. MB has bacteriostatic, antiviral and 
antifungal effects and acts on vascular musculature.20,21 
Additionally, MB, when excited by red light, produces 
oxygen “singlet”. Still, it presents the advantage of being 
low cost, easy to acquire and causes little damage to the 
patient.15
Recently, studies have shown the efficiency of PDT 
in the treatment of CL.6,14,22-24 One of the first reports 
about PDT for CL was made by Gardlo et al, in a study 
with a 34-year-old man with multiple injuries of CL by 
Leishmania donovani, in Libya. The patient was treated 
previously with sodium stibogluconate (Pentostam®), 
unsuccessfully, and later the treatment of 5 injuries was 
done with an association of methyl aminolevulinate 
(ALA) using red light (75 J/cm²) and 5 injuries with 
paromomycin ointment once a day. PDT was performed 
twice a week for 12 weeks and, later, once a week for 4 more 
weeks. All injuries treated with PDT obtained clinical and 
histopathological cure, without relapse after 10 months of 
after treatment follow-up and excellent cosmetic result. 
This fact confirms that PDT is a treatment superior to 
paromomycin, with a complete rate of response (93% and 
41%, respectively).19 
Studies have demonstrated the complete resolution of 
CL lesion, the decrease in the number of parasites in 
lesions and leishmanicidal activity to amastigote and 
promastigote forms.14,24,25 The favorable effect of PDT on 
CL is not only due to the straight parasiticidal effect, but 
also to the activation of the immune system with liberation 
of tumor necrosis factor, increase in the expression of 
adhesion molecules and increase of interleukin 6.22 
Among the studies that demonstrated benefit from 
the use of PDT in the treatment of CL, the majority 
used a porphyrin precursor (aminolevulinic acid or 
methylaminolevulinic acid) as photosensitizer agent and 
laser as light source.24-29 As these precursors and light 
source are high cost and considering the fact that a large 
number of CL cases occur in underdeveloped countries, 
dyes such as MB have been tested as photosensitizing 
agents and LED as light source. Peloi et al and Sbeghen 
et al utilized topic MB associated to red LED to treat CL, 
obtaining a decrease in lesion thickness and parasitic 
load.16,30 
As far as our knowledge goes, it has not been evaluated 
in vivo if PDT using LED as light source and MB as the 
photosensitizer in association with reference medicines 
could contribute to CL treatment. In this study, we 
evaluated the associations of PDT with LED and MB 
with Glucantime® or amphotericin B in the treatment 




Leishmania (Leishmania) amazonensis (MHOM/
BR/1977/LTB0016) was kept in mice by inoculation of 
107 parasites on the hind footpads. The animals were 
euthanized after anesthesia using ketamine hydrochloride 
(160 mg/kg) and xylazine (50 mg/kg), via intraperitoneal. 
Fragments of regional popliteal lymph nodes from 
the animals were inoculated aseptically in 199 culture 
medium (Gibco, New York, USA) pH 7.2 at 25°C in a 
B.O.D. incubator (Logen Scientific, Brazil). Protozoan 
cultures were kept through weekly subcultures.
Animals
For the experimental infection 90 days old female 
BALB/c mice were used, obtained from Biotério Central 
of the State University of Maringá, Maringá, Paraná, 
Brazil. During the experiment, the animals were kept 
in the Biotério Setorial at Leishmaniasis Laboratory in 
mini–insulators in ventilated racks (Alesco, Monte Mor, 
SP, Brazil) with controlled temperature, bright dark 
cycles, and environmental barriers. The animals were 
sedated with a combination of ketamine (80 mg/kg) and 
xylazine (16 mg/kg) before the procedure. At the end of 
treatment, to obtain biological material, the animals were 
anesthetized and euthanized.
do Nascimento Volpe et al
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Chemicals
Methylene blue (MB, C16H18C1N3S3H2O, MW 373.90 g 
mol-1) was prepared at 0.5% (m/v) in aqueous solution. 
Glucantime® (N-methylglucamine antimoniate, Sanofi 
Aventis, São Paulo, Brazil) and amphotericin B (Cristália, 
São Paulo, Brazil) were used as reference treatments.
Lighting System
Two lighting systems were prepared, having a plate of 
red LED formed by 6 rows of light-emitting diode (LED) 
units with 75 cm total length and 3 cm width, grasped by 
a wooden base at the sides of the board, distant 4 cm (in 
the first system) and 1 cm (in the second system) of the 
LED. Between the LEDs and the animals’ footpad a metal 
screen was put to support the animal. To individualize the 
treatment, each animal was separated in compartments 
of 15 cm using PVC tubes (polyvinyl chloride) with 
openings of 3 cm in diameter (Figure 1).
Two lighting systems were utilized with the LED 
maximum emission at 663 nm (Table 1).
The emission spectrum of LED was obtained in a 
spectrofluorometer Varian – Cary Eclipse (Agilent 
Technologies, USA) and light power was measured by 
a Portable Laser Power Meter (Edmund Optics Inc., 
USA). MB absorption spectrum (maximum 665 nm) 
was registered in the spectrophotometer model Varian – 
Cary50.
Experimental Infection
The animals were infected with intradermal inoculation 
containing 5 × 105 promastigote forms in the exponential 
phase of growth of L. (L.) amazonensis in 100 µL saline 
solution (0.9% NaCl, m/v) on the plantar pad of the right 
hind foot. The animals were examined weekly to evaluate 
the development of lesions (Figure 2).
The animals were divided into 6 groups: 
Gluc+PDT group (n = 5): treated with Glucantime® (100 
mg/kg/d = 28 mg Sb+5/kg/d) via intraperitoneal (IP) 
during 20 days (5 times a week for 4 weeks) and PDT after 
topic application of MB; 
Gluc group (n = 5): treated with Glucantime® (100 mg/
kg/d = 28 mg Sb+5/kg/d) via intraperitoneal for 20 days (5 
times a week for 4 weeks); 
PDT group (n = 4): treated with PDT after topical 
application of MB; 
Ampho+PDT group (n = 4): treated with amphotericin 
B (5 mg/kg/d) via intraperitoneal for 20 days (5 times a 
week for 4 weeks) and PDT therapy after topic application 
of MB; 
Figure 1. Lighting system consisting of a red LED plate formed by 6 
rows of LEDs with a length of 75 cm and width of 3 cm, secured by 
a wooden support on the sides of the plate where a metal screen was 
placed to support the animal: (A) First lighting system with LED plate 
at distance of 4 cm; (B) First lighting system with LED on; (C) Second 
lighting system with LED plate at short distance, of 1 cm; (D) Second 
lighting system with LED on; (E) each animal per individualized 
compartment – 15 cm with apertures of 3 cm in diameter; (F) details 
showing the individualized compartment with the animals and LED 
on.
Figure 2. Flowchart of the Experiment. Procedures performed from the 
infection of the animals (day 0) until the determination of the parasite 
load 165 days after the infection. 
Table 1. Characteristics of Lighting Systems Used
Lighting System




First 3 cm 2.63
Second 1 cm 4.27
 
Figure 2. lowchart of th  experiment. Procedures performed from the infection of the 
animals (day 0) until the determination of the parasite load 165 days after the infection.  
The animals were divided into 6 groups:  
Gluc+PDT group (n=5): treated with Glucantime® (100 mg/kg/d = 28 mg 
Sb+5/kg/d) via intraperitoneal (IP) during 20 days (5 times a week for 4 weeks) and PDT 
after topic application of MB;  
Gluc group (n=5): treated with Glucantime® (100 mg/kg/d = 28 mg Sb+5/kg/d) via 
intraperitoneal for 20 days (5 times a week for 4 weeks);  
PDT group (n=4): treated with PDT after topical application of MB;  
Ampho+PDT group (n=4): treated with amphotericin B (5 mg/kg/d) via 
intraperitoneal for 20 days (5 times a week for 4 weeks) and PDT therapy after topic 
application of MB;  
Ampho group (n=4); treated with amphotericin B (5 mg/kg/d) via intraperitoneal 
for 20 days (from Monday to Friday); and 
 Control group (n=3): infected and untreated. 
Treatment of Infected Animals 
The treatment was performed in 2 cycles. 
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Ampho group (n = 4); treated with amphotericin B (5 mg/
kg/d) via intraperitoneal for 20 days (5 times a week for 
4 weeks); and
Control group (n = 3): infected and untreated.
Treatment of Infected Animals
The treatment was performed in 2 cycles.
For the first cycle the first lighting system was used and, 
after the lesion development (approximately 45 days after 
infection), the 6 groups were treated. In this cycle, contact 
of MB with lesions lasted 30 minutes with sequent 
irradiation with red LED for 30 minutes, performed twice 
a week for 4 weeks.
After 105 days of infection, Gluc+PDT, PDT and 
Ampho+PDT groups were submitted to the second 
cycle of treatment, when the second lighting system was 
used with more time in contact between MB and lesion 
(1 hour) and more irradiation time (1 hour). Groups 
were irradiated more frequently in this second cycle, 3 
times a week for four weeks. In this treatment cycle, no 
intraperitoneal medication was applied. 
Evaluation of Lesion Evolution 
To evaluate the first treatment cycle, lesions were 
examined every 2 weeks (initiated 30 days after infection 
and ended after 90 days of infection), to measure the 
thickness and volume of both hind legs, using the 
pachymeter (Mitutoyo, Japan) and plestimometer (Ugo 
Basile S.R.L., Italy) respectively. To evaluate the second 
treatment cycle, a new check-up was made after 135 days 
of infection (after the end of second treatment cycle). 
Thickness and volume of the lesion were calculated by 
the difference between the infected paw and the non-
infected one. 
Determination of Parasite Load
The quantification of parasites in the lesion, the spleen 
and regional lymph nodes of animals was performed 
(165 days after infection) according to Buffet et al with 
modifications.31,32 The spleen, the lesion and popliteal 
lymph nodes of each animal were removed aseptically, 
weighed and macerated in cell disruptor in 199 
culture medium (Gibco, New York, NY, USA) pH 7.2. 
Suspensions were diluted from ¼ in the ratio of 2 in cell 
culture plate with 96 wells. Plates were incubated at 25ºC. 
Readings were made under an inverted light microscope 
(Olympus, New York, NY, USA) with 7, 14, 21, 28 days 
of incubation. The wells were examined searching viable 
promastigotes, considering a higher dilution in which 
at least one parasite was found as titer. The experiment 
was run in duplicates. Parasitic load calculation (number 
of parasites/gram of tissue) resulted by dividing the 
geometric media of the reciprocal positive titers and 
mass of organs (g) multiplied by 53, which is a fraction 
of suspension of each inoculated organ in the first well 
of the plate.
Histological Analysis 
After the end of the second treatment cycle (135 days 
after infection), euthanasia of the animals was performed 
by deepening anesthesia. The tissue material collected 
for histological analysis of injured footpad, spleen, and 
regional lymph nodes. Tissues were washed with saline 
solution, sectioned transversally, and immersed in 
buffered formalin fixative solution at 10% for 12 hours. 
After that, tissue was kept in alcoholic solution at 70% 
until the standard histological processing at Pathology 
Laboratory of the State University of Maringá. 
The tissues were dehydrated in bathing solutions with 
increasing alcoholic strength, diaphanized in xylol and 
included in paraffin. The paraffin blocks were sectioned 
in rotating semi-automatic microtome (CUT 5062-Slee 
Medical-Mainz Germany) in fragments of 5 µm thickness 
with space of 10 µm per cut and adhered to the histological 
lamina. Four to 5 cuts per lamina were distributed. 
Hematoxylin-eosin (HE) staining was performed for 
evaluation of histopathological changes. The analysis of 
the cuts and the capture of the images were performed 
with the help of optical light microscope O500R.
The tissue morphology was observed microscopically to 
study the occurrence of histopathological changes, such 
as the presence of amastigote nests, polymorphonuclear 
inflammatory infiltrate and/or mononuclear and tissue 
necrosis. These parameters were classified as absent (-), 
rare (+), moderate (+ +), or intense (+ + +), according 
to the frequency of changes. For this, we analyzed a total 
of 10 microscopic fields for each tissue fragment, and 
each field was divided into 4 quadrants. The presence of 
histopathological changes in only 1 of the quadrants was 
classified as rare (+), in 2 quadrants as moderate (+ +), 
and over three quadrants as intense (+ + +) (Figure 3).
Statistical Analysis
Results were analyzed by Software Bioestat 5.3. The 
evaluation of normality was performed through Lilliefors 
test. The values of volume and thickness were analyzed 
by Student’s t test. The analysis of the parasitic load was 
performed by analysis of variance (ANOVA). Five percent 
was considered as level of statistical significance.
 
Results
At the beginning of the first treatment cycle, forty days 
after infection, it was noted that the lesions did not present 
significant differences in relation to their thickness and 
volume (P > 0.05), demonstrating that the groups were 
not different from each other (Figures 4 and 5).
At the beginning and the end of the first treatment cycle 
(45 and 75 days after infection, respectively), volume 
was reduced when comparing the Gluc+PDT, Gluc, 
Ampho+PDT and Ampho groups with the control 
group, but this decrease was not statistically significant 
(P > 0.05). At the end of the first treatment cycle, there 
was no significant difference (P > 0.05) of the volume of 
do Nascimento Volpe et al
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Figure 3. Histological Picture of the Infected Footpad of Mice 
Infected With Leishmania (Leishmania) amazonensis, in Hematoxylin 
and Eosin Stain. Reconstituted epidermis after treatment (arrow), 
mononuclear inflammatory infiltrate (A), amastigote nests (B), and 
vascular congestion (C) (200x). In the upper left corner photograph in 
higher magnification (400x) of amastigote nests.
Figure 4. Evolution of the Lesion Volume of the Footpads of Mice Infected With Leishmania (Leishmania) amazonensis. The animals were infected 
with intradermal inoculation containing 5x105 of promastigotes forms of L. amazonensis on the right hind footpad and divided into 6 groups for 
treatment. Gluc+PDT group (n = 5) treated with Glucantime® (IP) and PDT-red LED and methylene blue (MB) in topical aqueous solution, Gluc 
group (n = 5) treated with Glucantime® (IP), PDT group (n = 4) treated with PDT-red LED and topical MB, control group (n = 3) with non-treated 
infected animals, Ampho+PDT group (n = 4) treated with amphotericin (IP) and PDT – red LED and topical MB and Ampho group (n = 4) treated 
with amphotericin (IP). Measurements were performed using the plestimometer. The volume of lesions was calculated by the difference between 
the volume of the infected and uninfected footpad and compared to the Control group (P > 0.05).
before and after the first treatment cycle, we noticed a 
reduction when comparing the control group with the 
Gluc+PDT and Gluc groups, but that reduction was not 
statistically significant (P > 0.05). In addition, we observed 
an increase in the thickness of the lesion in the Ampho, 
Ampho+PDT and PDT groups. At the end of the first 
treatment, there was no significant reduction of lesion 
thickness in any of the treated groups when compared to 
the control group (P > 0.05) (Figure 5).
In the second treatment cycle (measured between 90 and 
135 days after infection), increased lesion thickness was 
observed in all groups. After ending this treatment cycle 
(135 days after the infection), there was no reduction 
in lesion thickness in any of the treated groups when 
compared to the control group (P > 0.05) (Figure 5).
 In the analysis of parasite load quantification in different 
tissues, it was observed that in the popliteal lymph node 
there was a statistically significant difference (P ≤ 0.05) 
when we compared the Control group with the Gluc+PDT, 
Gluc, PDT and Ampho groups, which was not observed 
when comparing the Control group with the Ampho+PDT 
group (P > 0.05). In the other tissues, spleen and paw with 
the lesion, the values showed no significant difference in 
relation to the control group (P > 0.05) (Figure 6).
When analyzing histopathological changes of the animals’ 
footpads, we noticed that the group Gluc+PDT presented 
a smaller number of amastigote nests and lower intensity 
of mononuclear infiltrate when compared to the Gluc 
and PDT groups (Table 2 and Figure 7). In the spleen 
of the animals, we did not observe significant presence 
of amastigote nests or inflammatory tissue process. No 
necrosis was observed in any tissue sample. The analysis 
of regional lymph nodes was not possible due to the 
lesions between any of the treated groups in relation to the 
control group (Figure 4).
Analyzing the footpad volume measurements between 
the beginning and the end of the second treatment (90 
and 135 days after infection, respectively) there was a 
reduction in volume when comparing the curves of the 
control group with those of Gluc+PDT, but this difference 
was not statistically significant (P > 0.05). We also noticed 
an increase in volume in the lesions of the animals of the 
PDT group in relation to the control group (P > 0.05) with 
135 days (end of second treatment). None of the treated 
groups had a significant reduction in lesion volume when 
compared to the control group (P > 0.05)(Figure 4).
 In relation to the thickness measurement of the lesion, 
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and Eosin Stain. Reconstituted epidermis after treatment (arrow), 
mononuclear inflammatory infiltrate (A), amastigote nests (B), and 
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Figure 4. Evolution of the Lesion Volume of the Footpads of Mice Infected With Leishmania (Leishmania) amazonensis. The animals were infected 
with intradermal inoculation containing 5x105 of promastigotes forms of L. amazonensis on the right hind footpad and divided into 6 groups for 
treatment. Gluc+PDT group (n = 5) treated with Glucantime® (IP) and PDT-red LED and methylene blue (MB) in topical aqueous solution, Gluc 
group (n = 5) treated with Glucantime® (IP), PDT group (n = 4) treated with PDT-red LED and topical MB, control group (n = 3) with non-treated 
infected animals, Ampho+PDT group (n = 4) treated with amphotericin (IP) and PDT – red LED and topical MB and Ampho group (n = 4) treated 
with amphotericin (IP). Measurements were performed using the plestimometer. The volume of lesions was calculated by the difference between 
the volume of the infected and uninfected footpad and compared to the Control group (P > 0.05).
135 days (end of second treatment). None of the treated 
groups had a significant reduction in lesion volume when 
compared to the control group (P > 0.05)(Figure 4).
 In relation to the thickness measurement of the lesion, 
before and after the first treatment cycle, e noticed a 
reduction when comparing the control group with the 
Gluc+PDT and Gluc groups, but that reduction was not 
statistically significant (P > 0.05). I  addition, we observed 
an increase in the t ickness of the lesion in the Ampho, 
Ampho+PDT and PDT groups. At the end of the first 
treatment, the  was no signific nt reduction of lesion 
thickne s in any of he treated groups when compared to 
the control group (P > 0.05) (Figure 5).
In the second treatment ycle (measured betwe n 90 a d 
135 days after infection), increased lesion thickness was 
observed in all gr ups. After ending this treatment cycle 
(135 d ys after the infection), there was no reduction 
in lesion thickness in any of the treated groups wh n 
compared to the control group (P > 0.05) (Figure 5).
 In the analysis of parasite load quantification in different 
tissues, it was observed that in the popliteal lymph no e 
there was a statistically significant difference (P ≤ 0.05) 
when we compared t e Control group with the Gluc+PDT, 
Gluc, PDT and Ampho groups, which was not observed 
when comparing the Control group with the Ampho+PDT 
group (P > 0.05). In the other tissues, spleen and paw with 
the lesion, the values showed no significant difference in 
relation to the control group (P > 0.05) (Figure 6).
When analyzing histopathological changes of the animals’ 
footpads, we noticed that the group Gluc+PDT presented 
a smaller number of amastigote nests and lower intensity 
of mononuclear infiltrate when compared to the Gluc 
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Ampho+PDT and Ampho groups with the control 
group, but this decrease was not statistically sig ificant 
(P > 0.05). At the end of the first treatment cycle, there 
was no significant difference (P > 0.05) of the volume of 
lesions between any of the treated groups in relation to the 
control group (Figure 4).
Analyzing the footpad volume measurements between 
the beginning and the end of the second treatment (90 
and 135 days after infection, respectively) there was a 
reduction in volume when comparing the curves of the 
control group with those of Gluc+PDT, but this difference 
was not statistically significant (P > 0.05). We also noticed 
an increase in volume in the lesions of the animals of the 
PDT group in relation to the control group (P > 0.05) with 
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poor quality of the material after histological processing, 
making microscopic analysis impossible.
Discussion
Nowadays, all drugs available in Brazil for the treatment 
of leishmaniasis are intramuscular and intravenous. The 
drugs used are the pentavalent antimonials (first choice), 
amphotericin B and pentamidine (second choice). 
However, these drugs can cause many side effects, 
have a long treatment schedule and need an injectable 
administration.³ In view of these therapeutic difficulties, 
added to drugs resistance, other alternative therapies for 
cutaneous leishmaniasis have been evaluated, among 
them PDT.6,14-16
Several other studies have demonstrated the benefit 
of using PDT in the treatment of CL, but a porphyrin 
precursor (aminolevulinic acid or methylaminolevulinic 
acid) is the most used photosensitizing agent and the laser 
as a light source.24-29 As those precursors and light source 
are of high cost and considering that a great number of CL 
cases occur in underdeveloped countries, dyes like MB 
have been tested as photosensitizing agents and LED as 
Figure 6. Quantification of Parasite Load on the Spleen, Popliteal Lymph Nodes and Footpad Lesion of mice Infected With Leishmania (Leishmania) 
amazonensis. Gluc+PDT group (n = 3) treated with Glucantime® (IP) and PDT – red LED and methylene blue in topical aqueous solution, Gluc 
group (n = 3) treated with Glucantime® (IP), PDT group (n = 3) treated with PDT – red LED and topical MB, control group (n = 2) with infected and 
untreated animals, Ampho+PDT group (n = 3) treated with amphotericin (IP) and PDT – red LED and topical MB and Ampho group (n = 3) treated 
with amphotericin (IP). Lymph nodes from Gluc+PDT, Gluc, Ampho and PDT groups, when compared to untreated control group (P < 0.05). 
Figure 5. Evolution of Lesion Thickness in the Footpads of Mice Infected With Leishmania (Leishmania) amazonensis. Gluc+PDT group (n = 5) treated 
with Glucantime® (IP), and PDT – red LED and methylene blue (MB) topical aqueous solution, Gluc group (n = 5) treated with Glucantime® (IP), 
PDT group (n = 4) treated with PDT- red LED and topical MB, control group (n = 3) with non-treated infected animals, Ampho+PDT group (n = 4) 
treated with amphotericin (IP) and PDT – red LED and topical MB and Ampho group (n = 4) treated with amphotericin (IP). Measurements were 
performed using the pachymeter. Lesion thickness was calculated by the difference between the thickness of the infected and uninfected paws and 
compared to the control group (P > 0.05).
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of the animals, we did not observe significant presence 
of amastigote nests or inflammatory tissue process. No 
necrosis was observed in any tissue sample. The analysis 
of regional lymph nodes was not possible due to the 
poor quality of the material after histological processing, 
making microscopic analysis impossible.
Discussion
Nowadays, all drugs available in Brazil for the treatment 
of leishmaniasis are intramuscular and intravenous. The 
drugs used are the pentavalent antimonials (first choice), 
amphotericin B and pentamidine (second choice). 
However, these drugs can cause many side effects, 
have a long treatment schedule and need an injectable 
administration.³ In view of these therapeutic difficulties, 
added to drugs resistance, other alternative therapies for 
cutaneous leishmaniasis have been evaluated, among 
them PDT.6,14-16
Several other studies have demonstrated the benefit 
of using PDT in the treatment of CL, but a porphyrin 
precursor (aminolevulinic acid or methylaminolevulinic 
acid) is the most used photosensitizing agent and the laser 
Figure 6. Quantification of Parasite Load on the Spleen, Popliteal Lymph Nodes and Footpad Lesion of mice Infected With Leishmania (Leishmania) 
amazonensis. Gluc+PDT group (n = 3) treated with Glucantime® (IP) and PDT – red LED and methylene blue in topical aqueous solution, Gluc 
group (n = 3) treated with Glucantime® (IP), PDT group (n = 3) treated with PDT – red LED and topical MB, control group (n = 2) with infected and 
untreated animals, Ampho+PDT group (n = 3) treated with amphotericin (IP) and PDT – red LED and topical MB and Ampho group (n = 3) treated 
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compared to the control group (P > 0.05).
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of the animals, we did not observe sign ficant presence 
of amastigote nests or inflammatory tissue process. No 
necrosis was observed in any tissue sample. The analysis 
of regional lymph nodes was not possible due to the 
poor quality of the material after histological processing, 
making microscopic analysis impossible.
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treated with amphotericin (IP) and PDT – red LED and topical MB and Ampho group (n = 4) treated with amphotericin (IP). Measurements were 
performed using the pachymeter. Lesion thickness was calculated by the difference between the thickness of the infected and uninfected paws and 
compared to the control group (P > 0.05).
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light source. Peloi et al and Sbeghen et al utilized topic MB 
associated with red LED to treat CL, obtaining a decrease 
in the thickness of the lesion and in the parasitic load.16,30
 In this study, we evaluated the association of PDT 
(MB+LED) with the reference drugs in CL treatment, and 
observed a reduction in lesion thickness and volume in 
some of the treated groups, but this difference was not 
statistically significant. However, there was a significant 
reduction in the parasitic load in the regional lymph 
node of the groups Gluc+PDT, Gluc, PDT and Ampho in 
comparison to the control group, without treatment.
The Gluc+PDT and Ampho+PDT groups, despite 
having reduced lesion size after treatment (total of 20 
IP injections), did not maintain such results after the 
end of the first therapeutic regimen, since there was a 
considerable and abrupt increase of the lesion after the 
end of the first cycle (75 days) and the measurements with 
90 days (Figure 5). The doses, number of injections and 
route of administration used are similar to those used in 
other studies that have achieved therapeutic success.30,33,34 
Figure 7. Analysis of Frequency of Amastigote Nests Found on 
Injured Footpads of Mice Infected With Leishmania (Leishmania) 
amazonensis. Gluc+PDT group (n=3) treated with Glucantime® (IP) 
and PDT – red LED and methylene blue in topical aqueous solution, 
Gluc group (n=3) treated with Glucantime® (IP), PDT group (n=3) 
treated with PDT – red LED and topical methylene blue. Frequency 
of amastigote nests: absent (-) =, rare (+) = 1, moderate (++) =2 or 
intense (+++) =3.
Table 2. Histological analysis of injured footpad, lymph node and 
spleen of mice infected with Leishmania (Leishmania) amazonensis
Groupsa Gluc Gluc+PDT PDT
Amastigote 
nests 
Footpads ++ + ++
Lymph nodes + + +
Spleen - - -
Mononuclear 
infiltrate
Footpads ++ + +
Lymph nodes + + +
Spleen - - -
a Gluc+PDT group (n=3) treated with Glucantime® (IP) and PDT – red 
LED and methylene blue in topical aqueous solution; Gluc group (n=3) 
treated with Glucantime® (IP); PDT group (n=3) treated with PDT – red 
LED and topical MB. The frequency of histopathological changes was 
graded into absent = (-), rare = (+), moderate = (++) or intense = (+++).
However, the total number of PDT sessions was only 
8 in the first cycle of treatment and 12 in the second 
cycle, which differed from the other experiments, which 
performed a total of 36 irradiation sessions, in addition to 
using hamsters and not mice as in this study.16,30 Thus, we 
believe that a longer treatment with PDT may contribute 
to a greater reduction in the volume and thickness of the 
lesions. 
As observed in Figure 4 and 5, Ampho+PDT group did 
not present a significant difference in relation to the 
measures of volume and thickness of the paws when 
compared to the control group. One hypothesis would be 
the fact that amphotericin B (organic compound), being 
an antifungal of the class of the polyenes and possessing 
a number of double bonds of carbon, can be an excellent 
target for the singlet oxygen (1O2) generated in the 
reaction. The 1O2 formed in the PDT is highly oxidizing 
and attacks double bonds and conjugated rings. This 
way, it would be consumed in the attack to amphotericin 
B, and not in the elimination of the protozoa, reducing 
the therapeutic power of this chemotherapy and, also, of 
the photodynamic activity, which does not occur with 
pentavalent antimony (inorganic compound), probably 
due to its high oxidative power.
The results detected in the PDT group do not confirm the 
results found in previous studies.16,30 This fact may have 
been influenced by the distance from the light source to 
the lesion, by the frequency of irradiation and the total 
number of sessions for the treatment. Peloi et al and 
Sbeghen et al evaluated the use of PDT in experimentally 
infected hamsters. The source of irradiation used was 
located close to the lesion, the irradiation frequency 
applied was three times a week for a total of three months 
of treatment with a significant reduction in lesion size.16,30 
In the present study, two treatment cycles were performed 
with two different lighting models. In the first one, the 
LED was used 4 cm away from the lesion, irradiating for 
30 minutes 2 times a week for 4 weeks. In the second, 
the LED was used 1 cm away from the lesion and the 
irradiation was for 1 hour, 3 times a week for 4 weeks. 
We believe that, after the changes made in the second 
system, the results were not satisfactory as the lesion 
was already in advanced evolution. The lighting system 
used differed from those used in previous works.16,30 
Since there is no need to anesthetize the animals at each 
treatment, avoiding stress for the mice and risk of death 
secondary to anaesthesia use, in this system, the animal is 
in continuous movement, which may have influenced the 
angle of incidence of the LED and the total time of light 
absorption by MB in the lesion.
 The results of the histological evaluation of the infected 
paw showed that the Gluc+PDT group presented 
advantages in comparison with the Gluc and PDT groups. 
The moderate presence of nests of amastigote forms of 
the parasite and predominance of mononuclear infiltrate, 
with the absence of polymorphonuclear infiltrate, indicate 
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as a light source.24-29 As those precursors and light source 
are of high cost and considering that a great number of CL 
cases occur in underdeveloped countries, dyes like MB 
have been tested as photosensitizing agents and LED as 
light source. Peloi et al and Sbeghen et al utilized topic MB 
associated with red LED to treat CL, obtaining a decrease 
in the thickness of the lesion and in the parasitic load.16,30
 In this study, we evaluated the association of PDT 
(MB+LED) with the reference drugs in CL treatment, and 
observed a reduction in lesi n thickness and volume in 
some of the treated groups, but this difference was not 
statistically significant. However, there was a significant 
reduction in the parasitic lo d in t e region l lymph 
no e of the groups Gluc+PDT, Gluc, PDT and Ampho in 
mparison to the control group, without treatment.
The Gluc+PDT and Ampho+PDT groups, despite 
having reduced lesion size after treatment (total of 20 
IP injections), did not maintain such results after the 
end of the first t erapeutic regimen, sin e there was a 
considerable and abrupt increase of the lesion after the 
Figure 7. An lysis of Frequency of Amastigote Nests Found on 
Injured Footpads of Mice Infected With Leishmania (Leishmania) 
mazonensis. Gluc+PDT group (n=3) treated with Glucantime® (IP) 
and PDT – red LED and methylene blue in topical aqueous solution, 
Gluc group (n=3) t ated with Glucanti ® (IP), PDT group ( =3) 
tre ted with PDT – red LED and topical methylene blue. Frequency 
of amastigote nests: absent (-) =, rare (+) = 1, moderate (++) =2 or 
intense (+++) =3.
Table 2. Histological analysis of injured footpad, lymph node and 
spleen of mice infected with Leishmania (Leishmania) amazonensis
Groupsa Gluc Gluc+PDT PDT
Amastigote 
nests 
Footpads ++ + ++
Lymph nodes + + +
Spleen - - -
Mononuclear 
infiltrate
Footpads ++ + +
Lymph nodes + + +
Spleen - - -
a luc P T group (n 3) treated ith lucanti e  (IP) and PDT – red 
LE  and ethylene blue in topical aqueous solution; luc group (n=3) 
treated ith lucanti e® (IP); P T group (n=3) treated ith PDT – red 
LE  and topical B. The frequency of histopathological changes was 





















end of the first cycle (75 days) and the measurements with 
90 days (Figure 5). The doses, number of injections and 
route of administration used are similar to those used in 
other studies that have achieved therapeutic success.30,33,34 
However, the total number of PDT sessions was only 
8 in the first cycle of treatment and 12 in the second 
cycle, which differed from the other experiments, which 
performed a total of 36 irradiation sessions, in addition to 
using hamsters and not mice as in this study.16,30 Thus, we 
believe that a longer treatment with PDT may contribute 
to a greater reduction in the volume and thickness of the 
lesions. 
As observed in Figure 4 and 5, Ampho+PDT group did 
not present a significant difference in relation to the 
measures of volume and thickness of the paws when 
compared to the control group. One hypothesis would be 
the fact that amphotericin B (organic compound), being 
an antifungal of the class of the polyenes and possessing 
a number of double bonds of carbon, can be an excellent 
target for the singlet oxygen (1O2) generated in the 
reaction. The 1O2 formed in the PDT is highly oxidizing 
and attacks double bonds and conjugated rings. This 
way, it would be consumed in the attack to amphotericin 
B, and not in the elimination of the protozoa, reducing 
the therapeutic power of this chemotherapy and, also, of 
the photodynamic activity, which does not occur with 
pentavalent antimony (inorganic compound), probably 
due to its high oxidative power.
The results detected in the PDT group do not confirm the 
results found in previous studies.16,30 This fact may have 
been influenced by the distance from the light source to 
the lesion, by the frequency of irradiation and the total 
number of sessions for the treatment. Peloi et al and 
Sbeghen et al evaluated the use of PDT in experimentally 
infected hamsters. The source of irradiation used was 
located close to the lesion, the irradiation frequency 
applied was three times a week for a total of three months 
of treatment with a significant reduction in lesion size.16,30 
In the present study, two treatment cycles were performed 
with two different lighting models. In the first one, the 
LED was used 4 cm away from the lesion, irradiating for 
30 minutes 2 times a week for 4 weeks. In the second, 
the LED was used 1 cm away from the lesion and the 
irradiation was for 1 hour, 3 times a week for 4 weeks. 
We believe that, after the changes made in the second 
system, the results were not satisfactory as the lesion 
was already in advanced evolution. The lighting system 
used differed from t ose used in previous w rks.16,30 
Since there is no need to anesthetize the animals at each 
treatment, avoiding stress for the mice and risk of death 
secondary to anaesthesia use, in this system, the animal is 
in continuous movement, whic  may h ve influenced the 
angle f incidence of the LED and the total time of light 
absorption by MB in the lesion.
 T e r sults of the histol gical evaluat on of he infect d 
paw showed that the Gluc+PDT group presented 
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a tendency of cure of the inflammatory process. In the 
Gluc and PDT groups, we observed an intense presence 
of mononuclear inflammatory infiltrate, in addition to 
the intense presence of macrophages filled with vacuoles 
containing amastigote forms. However, the frequency 
of amastigote nests in the PDT group differed from that 
found in the study by Sbeghen et al, which showed only 
rare amounts of amastigote nests in tissue macrophages 
in the footpads of hamsters treated with topical MB and 
PDT.26 The statistical evaluation of these data in our study 
could not be performed because the sample was reduced, 
since some organs could not be analyzed microscopically 
due to their poor quality after histological processing.
 The results presented show that although there were 
no significant differences in footpad (thickness and 
volume) evaluations, there was a tendency of lower 
growth, as we observed specially in the volume data. 
Volume measurements can be considered more reliable 
than those of thickness, as they are less influenced by 
the degree of ulceration of the lesion. In the evaluation 
of this parameter, the Gluc+PDT group had lower lesion 
volumes in comparison to the control group at the end of 
the first treatment cycle (75 days after infection) and also 
at the end of the second treatment cycle (135 days after 
infection). This finding is corroborated by the negativity 
of the parasitic load in all analyzed organs of the animals 
of this group.
Conclusion
These observations, in our point of view, indicate the 
possibility of using Glucantime® in combination with 
PDT (MB + LED) in order to reduce the time of treatment 
or the dose of medication, which is of first choice in the 
treatment of CL, with consequent reduction of the risk of 
side effects. However, new studies should be carried out to 
evaluate the use of different doses and time of treatment 
with Glucantime®, as well as periodicity, irradiation time, 
and the total number of PDT sessions with MB to obtain 
the clinical cure of CL lesions.
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